Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer

程凌霄; 陈立波

doi:10.3969/j.issn.1007-3969.2016.01.006

您当前的位置：

首页 >

文章列表页 >

Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer

更新时间：2025-12-31

- Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer
- China Oncology Vol. 26, Issue 1, Pages: 35-42(2016)
- 作者机构：
  
  上海交通大学附属第六人民医院核医学科,上海,200233
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2016.01.006
  CLC：
- Published Online：26 February 2016，
  
  Published：26 February 2016
- 稿件说明：
移动端阅览
程凌霄,陈立波.

程凌霄, 陈立波. Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer[J]. China Oncology, 2016, 26(1): 35-42.
程凌霄,陈立波. DOI： 10.3969/j.issn.1007-3969.2016.01.006.

程凌霄, 陈立波. Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer[J]. China Oncology, 2016, 26(1): 35-42. DOI： 10.3969/j.issn.1007-3969.2016.01.006.

摘要

131

I难治性分化型甲状腺癌(radioiodine-refractory differentiated thyroid cancer，RR-DTC)是目前甲状腺癌临床治疗领域的一大难题。维甲酸类药物、过氧化物酶体增殖物激活受体激动剂、DNA甲基化酶抑制剂及组蛋白脱乙酰化酶抑制剂都曾被用于诱导RR-DTC再分化并与

131

I联合治疗，但疗效并不显著。近年来，随着对RR-DTC分子机制认识的不断深入，靶向治疗等新的再分化治疗策略越来越多地被尝试用于治疗RRDTC。相比之下，分子靶向药物用于诱导RR-DTC重摄碘及介导

131

I治疗效果较好，可能具有良好的应用前景。

Abstract

Clinical management of radioiodine-refractory differentiated thyroid cancer (RR-DTC) is extremely difficult. Re-differentiation compounds

such as retinoids

peroxisome proliferator-activated receptor (PPAR) agonists

DNA methyltransferase inhibitors and histone deacetylase inhibitors

have been used in trials to increase iodine uptake in RR-DTC. However

data on these drugs failed to meet the initial high expectations. In recent years

targeted agents have been increasingly used in pre-clinical and clinical studies to induce re-differentiation and mediate

131

I therapy

and the outcomes are encouraging.

关键词

Keywords

references

Views

2998

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: advances in surgical treatment of differentiated thyroid cancer

Survival and cause-of-death analysis of 55 thousand thyroid cancer cases in China from a large single institution hospital-based cancer registry database

Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer

Research progress in epidemiology and risk factors of thyroid cancer

Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer (2023 edition)

Related Author

Jugao FANG

Qian SHI

Qinghai JI

Ying ZHENG

Yu WANG

Jing YUAN

Changming ZHOU

Miao MO

Related Institution

Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University

Shanghai Engineering Research Center of Artificial Intelligence Technology for Tumor Diseases

School of Public Health, Fudan University

Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰